You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: August 2022 to March 2024

AbstractFullPdf
Aug 202210521079378
Sep 2022380388149
Oct 2022310312117
Nov 202221621781
Dec 202216917359
Jan 202315916059
Feb 202312813163
Mar 202314915253
Apr 2023818241
May 2023878743
Jun 2023939554
Jul 2023748036
Aug 202310210339
Sep 202310110450
Oct 2023949537
Nov 2023929344
Dec 2023747448
Jan 2024878872
Feb 2024676738
Mar 2024818177
Total359636611538